Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2Ineu
1998

Prolonged Tumor Retention of a Human Diabody Targeting HER2/neu

Sample size: 10 publication Evidence: high

Author Information

Author(s): GP Adams, R Schier, AM McCall, RS Crawford, EJ Wolf, LM Weiner, JD Marks

Primary Institution: Fox Chase Cancer Center; University of California, San Francisco

Hypothesis

Can diabody molecules improve the delivery of therapeutic agents to tumors?

Conclusion

The C6.5 diabody format provides a significant advantage in tumor targeting compared to the scFv monomer.

Supporting Evidence

  • The C6.5 diabody showed a 40-fold increase in affinity for HER2/neu compared to the scFv.
  • Diabody retention in tumors was significantly higher than in blood and normal tissues.
  • At 4 hours post-injection, the diabody retained 10.1 %ID g-1 in tumors.
  • Diabody showed a slower elimination phase from circulation compared to the scFv.
  • Significantly more diabody was retained in tumors than in any other organ at all time points studied.

Takeaway

This study shows that a special type of antibody called a diabody can stick to tumors longer than regular antibodies, which might help deliver medicine better.

Methodology

The study involved creating a diabody from a specific scFv and testing its retention in tumor-bearing mice using biodistribution studies.

Limitations

The study primarily focused on one type of tumor and may not generalize to all cancers.

Participant Demographics

Six- to eight-week-old CB. 17 Icr scid mice bearing human ovarian carcinoma SK-OV-3 cells.

Statistical Information

P-Value

0.00043

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication